IRCT20210811052150N1 IRCT 2023-01-28 Shahid Beheshti University of Medical Sciences effect of Empagliflozine on the Non-Alchoholic Fatti Liver Disease The effect of Empagliflozine on the Non-Alcoholic Fatty Liver Disease in patients with type 2 diabetes mellitus 2021-08-11 anticipated 140 Complete https://irct.ir/trial/58557 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization will be simple and for each patient according to labeling initial amounts of the placebo (control group) and Empagliflozine(treatment group),using a randomizednumber chart.these same numbers will be written and sealed,and placed in a box for allocation concealment.The course of treatment for each patient will be selected by choosing the random numbers concealed in the box at the beginning of the study, Blinding description: In this study,blinding will e done for the patients as well aspart of the researchers who have the role of clinical caregivers and outcome assessors by coding packages containing empagliflozin and placebo which are apparently the same.Then these codes will be the number of patients in one envelope,will be cast and chosen randomaly. 2-3 Non-Alchoholic Fatty Liver Disease. Intervention 1: Intervention group: Patients with Non-Alcoliholic Fatty Liver disease and type 2 Diabetes are under intervention with Empagliflozine at a dose of 10 and 25 mg based on FBS and HbA1c for 6 months and after 3 and 6 months in terms of FBS,HbA1c,AST,ALT,ALKP and degree of fatty liver they are examined in MRI and ultrasound. Intervention 2: Control group: Patients with Non-Alcoliholic Fatty Liver disease and type 2 Diabetes under standard diabetes treatment with placebo drug that did not contain empagliflozin based on FBS and HbA1c are monitored for 6 months in terms of FBS,HbA1c,AST,ALT,ALKP and liver grade fat is checked in MRI and ultrasound. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information